Skip to content
Medical Health Aged Care

Medidata Announces Rave Lite to Support Growth in Early and Late-Stage Clinical Trials

Medidata 3 mins read

New offering leverages Medidata Rave EDC, making the world’s leading electronic clinical data capture available to market segments historically lacking access to the cutting-edge technology


NEW YORK--BUSINESS WIRE--

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Medidata Rave Lite, an extension of the company’s gold-standard clinical research software, Medidata Rave EDC, designed explicitly for Phase I and Phase IV studies. Regardless of company size, therapeutic focus, or pipeline, Rave Lite provides efficient electronic clinical data capture (EDC), management, and analysis solutions with a tailored pricing model.

While EDC is a fundamental building block of clinical trials, technology fragmentation across phases leads to integration challenges and delays in startup times. In particular, the lack of access to innovative technology disproportionately affects early- and late-stage studies. Having addressed these challenges in over 34,000 trials, Medidata is now offering superior options for Phase I and Phase IV studies with Rave Lite.

With Medidata Designer integration, study builders can design Phase I and Phase IV trials with speed and precision, and with the continued use of AI, potential study misconfigurations are reduced while securing data integrity. Thus, Rave Lite offers a consistent experience without sacrificing the advanced power of Rave EDC.

“Rave Lite addresses a critical need in the market for early and late-stage trials, offering a streamlined solution built on our trusted Rave EDC platform,” said Tom Doyle, chief technology officer, Medidata. “By giving our customers the ability to use one EDC ubiquitously across all phases, customers gain the flexibility to scale their studies while maintaining the high standards that have long defined Medidata’s solutions.”

Rave EDC was recently recognized as the leading provider by Everest Group‘s first-ever PEAK Matrix® for its effectiveness in simplifying clinical trials for sponsors and CROs while ensuring data quality and integrity.

Medidata will showcase Rave Lite at NEXT New York, the premier clinical trials conference hosted by the company, in New York City on November 13 and 14. The solution will be made available to customers in early 2025. For more information on how Rave Lite can benefit research, click here.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.


Contact details:

Medidata PR
[email protected]

Analyst Relations
[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.